Home Healthcare Medical Devices Cyclosporine Market

Cyclosporine Market Size, Share & Trends Analysis Report By Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye Disease, Other Indication), By Route of Administration (Oral, Parenteral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: April 14, 2026 | Author: Dhanashri B | Format: | Report Code: SR7817DR | Pages: 160
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cyclosporine Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Transplant Rejection Prophylaxis
    2. Rheumatoid Arthritis
    3. Psoriasis
    4. Autoimmune Myasthenia Gravis
    5. Dry Eye Disease
    6. Other Indication
  2. Cyclosporine Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Parenteral
  3. Regional Cyclosporine Market
    1. North America
      1. North America Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. North America Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. U.S. Cyclosporine Market
        1. U.S. Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. U.S. Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      4. Canada Cyclosporine Market
        1. Canada Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Canada Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
    2. Europe
      1. Europe Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. Europe Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. U.K. Cyclosporine Market
        1. U.K. Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. U.K. Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      4. Germany Cyclosporine Market
        1. Germany Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Germany Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      5. France Cyclosporine Market
        1. France Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. France Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      6. Spain Cyclosporine Market
        1. Spain Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Spain Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      7. Italy Cyclosporine Market
        1. Italy Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Italy Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      8. Russia Cyclosporine Market
        1. Russia Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Russia Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      9. Nordic Cyclosporine Market
        1. Nordic Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Nordic Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      10. Benelux Cyclosporine Market
        1. Benelux Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Benelux Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      11. Rest of Europe Cyclosporine Market
        1. Rest of Europe Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Rest of Europe Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
    3. APAC
      1. APAC Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. APAC Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. China Cyclosporine Market
        1. China Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. China Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      4. Korea Cyclosporine Market
        1. Korea Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Korea Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      5. Japan Cyclosporine Market
        1. Japan Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Japan Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      6. India Cyclosporine Market
        1. India Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. India Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      7. Australia Cyclosporine Market
        1. Australia Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Australia Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      8. Taiwan Cyclosporine Market
        1. Taiwan Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Taiwan Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      9. South East Asia Cyclosporine Market
        1. South East Asia Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. South East Asia Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      10. Rest of Asia-Pacific Cyclosporine Market
        1. Rest of Asia-Pacific Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Rest of Asia-Pacific Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
    4. Middle East and Africa
      1. Middle East and Africa Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. Middle East and Africa Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. UAE Cyclosporine Market
        1. UAE Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. UAE Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      4. Turkey Cyclosporine Market
        1. Turkey Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Turkey Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      5. Saudi Arabia Cyclosporine Market
        1. Saudi Arabia Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Saudi Arabia Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      6. South Africa Cyclosporine Market
        1. South Africa Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. South Africa Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      7. Egypt Cyclosporine Market
        1. Egypt Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Egypt Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      8. Nigeria Cyclosporine Market
        1. Nigeria Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Nigeria Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      9. Rest of MEA Cyclosporine Market
        1. Rest of MEA Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Rest of MEA Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
    5. LATAM
      1. LATAM Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      2. LATAM Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
      3. Brazil Cyclosporine Market
        1. Brazil Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Brazil Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      4. Mexico Cyclosporine Market
        1. Mexico Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Mexico Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      5. Argentina Cyclosporine Market
        1. Argentina Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Argentina Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      6. Chile Cyclosporine Market
        1. Chile Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Chile Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      7. Colombia Cyclosporine Market
        1. Colombia Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Colombia Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
      8. Rest of LATAM Cyclosporine Market
        1. Rest of LATAM Cyclosporine Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Transplant Rejection Prophylaxis
          2. Rheumatoid Arthritis
          3. Psoriasis
          4. Autoimmune Myasthenia Gravis
          5. Dry Eye Disease
          6. Other Indication
        2. Rest of LATAM Cyclosporine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Parenteral
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.